BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 191 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2019. The put-call ratio across all filers is 0.20 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $10,754,000 | +7.3% | 71,140 | +3.4% | 0.02% | +20.0% |
| Q2 2022 | $10,026,000 | +26.2% | 68,810 | +2.2% | 0.02% | +50.0% |
| Q1 2022 | $7,946,000 | +28.2% | 67,324 | +49.7% | 0.01% | +25.0% |
| Q4 2021 | $6,199,000 | -31.2% | 44,985 | -30.6% | 0.01% | -42.9% |
| Q3 2021 | $9,007,000 | +25.0% | 64,841 | -12.6% | 0.01% | +55.6% |
| Q2 2021 | $7,205,000 | +95.5% | 74,215 | +37.6% | 0.01% | +80.0% |
| Q1 2021 | $3,686,000 | -51.8% | 53,928 | -39.6% | 0.01% | 0.0% |
| Q4 2020 | $7,650,000 | +127.8% | 89,262 | +72.9% | 0.01% | 0.0% |
| Q3 2020 | $3,358,000 | -2.8% | 51,613 | +9.2% | 0.01% | -16.7% |
| Q2 2020 | $3,455,000 | +348.7% | 47,258 | +96.8% | 0.01% | +200.0% |
| Q1 2020 | $770,000 | -53.5% | 24,010 | -21.1% | 0.00% | -33.3% |
| Q4 2019 | $1,657,000 | – | 30,436 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |